The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (her2), was the first her2-targeted therapy that clearly demonstrated a significant clinical benefit for wome...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Multimed Inc.
2009
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050/ |